Aflibercept


zaltrap

نام تجاری

SANOFI

شرکت تولیدکننده

It is an inhibitor of vascular endothelial growth factor. It is designed to bind to VEGF-A, VEGF-B, and placental growth factor (PIGF).

مکانیسم اثر

In November 2011 the United States FDA approved aflibercept for the treatment of wet macular degeneration.On August 3, 2012 the United State FDA approved Zaltrap (ziv-aflibercept) for use in combination with 5-fluorouracil, leucovorin and irinotecan to treat adults with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin‑containing regimen.

تأییدات بین‌المللی (FDA, NICE,…..)

۴ mg per kg as an intravenous (IV) infusion over 1 hour every two weeks. Administer ZALTRAP prior to any component of the FOLFIRI regimen on the day of treatmentContinue ZALTRAP until disease progression or unacceptable toxicity.

اندیکاسیون‌های دوز دارو و فواصل تجویز

In April 2011 Regeneron reported that aflibercept improved its primary endpoint of overall survival in the Velour phase III clinical trial for second-line treatment for metastatic colorectal cancer (mCRC).

مطالعاتی که بر اساس آن تآئیدیه گرفته است

Do not administer as an IV push or bolus

نحوه‌ی تجویز

  • ۱۰۰ mg per 4 mL (25 mg per mL) solution, single-use vial
  • ۲۰۰ mg per 8 mL (25 mg per mL) solution, single-use

اشکال دارویی

قیمت

Hemorrhage, neutropenia, diarrhea, hypertension, leukopenia, stomatitis, fatigue, proteinuria, and asthenia.

عوارض شایع

Gastrointestinal Perforation

Compromised Wound Healing

Fistula Formation

Arterial Thromboembolic Events

Reversible Posterior Leukoencephalopathy Syndrome (RPLS)

عوارض شدید

at least 4 weeks prior to elective surgery, and do not resume ZALTRAP for at least 4 weeks following major surgery and until the surgical wound is fully healed.

Do not administer ZALTRAP in patients with severe hemorrhage.

کنترااندیکاسیون

There are no known significant interactions.

تداخل دارویی

دسترسی در ایران